- Home
- CLLS vs ASMB Comparison
CLLS vs ASMB Comparison
Compare CLLS & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | ASMB |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 442.9M |
| IPO Year | 2014 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CLLS | ASMB |
|---|---|---|
| Price | $3.22 | $23.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $8.33 | ★ $44.20 |
| AVG Volume (30 Days) | 32.4K | ★ 188.1K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.98 | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $16.80 |
| 52 Week High | $5.48 | $39.71 |
Technical Indicators
Market Signals| Indicator | CLLS | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 37.61 | 35.92 |
| Support Level | $3.05 | $20.23 |
| Resistance Level | $3.83 | $30.80 |
| Average True Range (ATR) | 0.17 | 1.51 |
| MACD | -0.03 | -0.34 |
| Stochastic Oscillator | 24.19 | 19.64 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.